特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
425936

世界の呼吸器系疾患治療薬・デバイス市場の分析

Global Respiratory Drugs and Devices Market Research and Forecast, 2018-2023

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
世界の呼吸器系疾患治療薬・デバイス市場の分析
出版日: 2018年03月01日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の呼吸器系疾患治療薬・デバイス市場について調査分析し、市場影響要因、地域別の規制・政策、市場決定要因、収益予測、主要企業のプロファイルや最近の動向など、体系的な情報を提供しています。

第1章 レポートサマリー

第2章 市場概要と考察

  • 定義
  • ギャップ分析
  • 歴史的分析
  • 現ジアの市場動向
  • アナリストの考察
  • 規制
  • 呼吸器系疾患

第3章 市場決定要因

  • 促進要因
  • 抑制要因
  • 機会

第4章 市場区分

  • デバイス別
  • 薬剤別
  • エンドユーザー別

第5章 競合情勢

  • 主要戦略分析
  • 主要企業分析

第6章 地域別分析

  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第7章 企業プロファイル

  • PHILIPS HEALTHCARE
  • NOVARTIS
  • GLAXOSMITHKLINE
  • ASTRAZENECA
  • COVIDIEN PLC
  • ROCHE
  • BAXTER INTERNATIONAL
  • GE HEALTHCARE LIMITED
  • AIR LIQUIDE S.A.
  • 大塚製薬
  • PFIZER
  • MERCK AND CO.
  • BOEHRINGER INGELHEIM
  • TEVA PHARMACEUTICALS
  • COMPUMEDICS LIMITED
  • FISHER AND PAYKEL HEALTHCARE CORP. LTD
  • CHART INDUSTRIES
  • INVACARE CORPORATION
  • DRAGER MEDICAL GMBH
  • HAMILTON MEDICAL AG
図表

List of Tables

  • TABLE # 1 GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2023, ($ MILLION)
  • TABLE # 2 GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY PRODUCT 2017-2023, ($ MILLION)
  • TABLE # 3 GLOBAL THERAPEUTICS DEVICES MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 4 GLOBAL RESPIRATORY POSITIVE AIRWAY PRESSURE DEVICES MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 5 GLOBAL RESPIRATORY CPAP DEVICES MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 6 GLOBAL RESPIRATORY APAP DEVICES MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 7 GLOBAL RESPIRATORY BPAP MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 8 GLOBAL RESPIRATORY MASKS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 9 GLOBAL RESPIRATORY NASAL MASKS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 10 GLOBAL RESPIRATORY FULL-FACE MASKS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 11 GLOBAL RESPIRATORY NASAL PILLOW MASKS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 12 GLOBAL RESPIRATORY ORAL MASKS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 13 GLOBAL VENTILATORS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLIONS)
  • TABLE # 14 GLOBAL ADULT VENTILATORS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 15 GLOBAL INFANT/NEONATAL VENTILATORS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 16 GLOBAL RESPIRATORY NEBULIZERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 17 GLOBAL RESPIRATORY HUMIDIFIERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 18 GLOBAL RESPIRATORY HEATED HUMIDIFIERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 19 GLOBAL RESPIRATORY PASSOVER HUMIDIFIERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 20 GLOBAL RESPIRATORY OXYGEN CONCENTRATOR MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 21 GLOBAL RESPIRATORY FIXED OXYGEN CONCENTRATOR MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 22 GLOBAL RESPIRATORY PORTABLE OXYGEN CONCENTRATOR MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 23 GLOBAL RESPIRATORY INHALERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 24 GLOBAL RESPIRATORY DPIS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 25 GLOBAL RESPIRATORY METERED DOSE INHALERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 26 GLOBAL RESPIRATORY REUSABLE RESUSCITATORS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 27 GLOBAL RESPIRATORY ADULT REUSABLE RESUSCITATORS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 28 GLOBAL RESPIRATORY INFANT/NEONATAL REUSABLE RESUSCITATORS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 29 GLOBAL RESPIRATORY NITRIC OXIDE DELIVERY UNIT MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 30 GLOBAL RESPIRATORY OXYGEN HOODS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 31 GLOBAL DIAGNOSTIC AND MONITORING MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 32 GLOBAL RESPIRATORY PULSE OXIMETERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 33 GLOBAL RESPIRATORY PULSE OXIMETERS SENSORS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 34 GLOBAL RESPIRATORY PULSE OXIMETERS EQUIPMENT MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 35 GLOBAL RESPIRATORY CAPNOGRAPHS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 36 GLOBAL RESPIRATORY GAS ANALYZERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 37 GLOBAL RESPIRATORY SPIROMETERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 38 GLOBAL RESPIRATORY PSG DEVICES MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 39 GLOBAL RESPIRATORY PEAK FLOW METERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 40 GLOBAL RESPIRATORY CONSUMABLES AND ACCESSORIES METERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 41 GLOBAL RESPIRATORY DISPOSABLE MASK METERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 42 GLOBAL RESPIRATORY DISPOSABLE RESUSCITATORS METERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 43 GLOBAL RESPIRATORY TRACHEOSTOMY TUBE METERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 44 GLOBAL RESPIRATORY NASAL CANNULAS METERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 45 GLOBAL RESPIRATORY OTHER CONSUMABLES AND ACCESSORIES METERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 46 GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY RESPIRATORY DRUG 2017-2023, ($ MILLION)
  • TABLE # 47 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION 2017-2023, ($ MILLION)
  • TABLE # 48 GLOBAL ORAL RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 49 GLOBAL INJECTABLE RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 50 GLOBAL INHALABLE RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 51 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS 2017-2023, ($ MILLION)
  • TABLE # 52 GLOBAL ANTICHOLINERGICS MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 53 GLOBAL ANTIHISTAMINES MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 54 GLOBAL BETA2 AGONISTS MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 55 GLOBAL ANTIASTHMATICS COMBINATIONS MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 56 GLOBAL CORTICOSTEROIDS MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 57 GLOBAL LEUKOTRIENE INHIBITORS MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 58 GLOBAL MAST CELL STABILIZERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 59 GLOBAL PDE4 INHIBITORS MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 60 GLOBAL BRONCHODILATORS MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 61 GLOBAL DECOGESTANTS MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 62 GLOBAL EXPECTORANTS MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 63 GLOBAL OTHER RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 64
  • TABLE # 65 GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023, ($ MILLION)
  • TABLE # 66 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS BY APPLICATIONS 2017-2023, ($ MILLION)
  • TABLE # 67 GLOBAL HOME CARE MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 68 GLOBAL OTHER END USERS MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 69 NORTH AMERICA RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY PRODUCT 2017-2023, ($ MILLION)
  • TABLE # 70 NORTH AMERICA RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY RESPIRATORY DRUGS 2017-2023, ($ MILLION)
  • TABLE # 71 NORTH AMERICA RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023, ($ MILLION)
  • TABLE # 72 EUROPE RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY PRODUCT 2017-2023, ($ MILLION)
  • TABLE # 73 EUROPE RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY RESPIRATORY DRUGS 2017-2023, ($ MILLION)
  • TABLE # 74 EUROPE RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023, ($ MILLION)
  • TABLE # 75 APAC RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY PRODUCT 2017-2023, ($ MILLION)
  • TABLE # 76 APAC RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY RESPIRATORY DRUGS 2017-2023, ($ MILLION)
  • TABLE # 77 APAC RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023, ($ MILLION)
  • TABLE # 78 REST OF THE WORLD RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY PRODUCT 2017-2023, ($ MILLION)
  • TABLE # 79 REST OF THE WORLD RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY RESPIRATORY DRUGS 2017-2023, ($ MILLION)
  • TABLE # 80 REST OF THE WORLD RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023, ($ MILLION)

List of Figures

  • FIGURE # 1 GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET SHARE BY PRODUCT 2017 VS 2023 (IN %)
  • FIGURE # 2 GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET SHARE BY RESPIRATORY DRUGS 2017 VS 2023 (IN %)
  • FIGURE # 3 GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET SHARE BY END USERS 2017 VS 2023 (IN %)
  • FIGURE # 4 GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET SHARE BY GEOGRAPHY 2017 VS 2023 (IN %)
  • FIGURE # 5 NORTH AMERICA RESPIRATORY DRUGS AND DEVICES MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 6 US RESPIRATORY DRUGS AND DEVICES MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 7 CANADA RESPIRATORY DRUGS AND DEVICES MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 8 EUROPEAN RESPIRATORY DRUGS AND DEVICES MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 9 UK RESPIRATORY DRUGS AND DEVICES MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 10 FRANCE RESPIRATORY DRUGS AND DEVICES MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 11 GERMANY RESPIRATORY DRUGS AND DEVICES MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 12 ITALY RESPIRATORY DRUGS AND DEVICES MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 13 SPAIN RESPIRATORY DRUGS AND DEVICES MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 14 ROE RESPIRATORY DRUGS AND DEVICES MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 15 ASIA PACIFIC RESPIRATORY DRUGS AND DEVICES MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 16 INDIA RESPIRATORY DRUGS AND DEVICES MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 17 CHINA RESPIRATORY DRUGS AND DEVICES MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 18 JAPAN RESPIRATORY DRUGS AND DEVICES MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 19 ROAPAC RESPIRATORY DRUGS AND DEVICES MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 20 REST OF THE WORLD RESPIRATORY DRUGS AND DEVICES MARKET SIZE 2017-2023 ($MILLION)
目次
Product Code: MD-1203

Respiratory drugs and devices market is expected to grow at a CAGR of 7% for the forecasted period of 2018-2023. The market is driven by growing prevalence of respiratory diseases and disorders. There is been constant growth in the number of cases asthma and COPD. Asthma and COPD account for approximately 60% of the respiratory drugs and devices market. An aging population and major lifestyle changes have led to rise in respiratory diseases. Habits such as overeating, smoking, lack of exercise and other major lifestyle changes are causing respiratory diseases. Cases of the respiratory disorder are also on a rise in new-born.

Respiratory drugs and devices companies are concentrating on developing new products. Companies are expanding their product portfolios and increasing their R&D budget. Major respiratory devices include therapeutic devices such as masks, ventilators, humidifiers, positive airway pressure devices and other devices. Other respiratory devices include diagnostic and monitoring devices and consumables and accessories meters. Respiratory drugs segmented on the basis of route of administration and drugs class.

For Related Reports: Medical Devices Industry

The regional outlook of global respiratory drugs and devices market includes: North America, Europe, APAC, and Rest of the world. North America is the leading market. The market is expected to grow at a stable CAGR. North American market is driven by high sales of branded drugs and a high number of patient diagnosed and treated for respiratory diseases. North American marker is followed by Europe, Asia Pacific and Rest of the world. Asia Pacific market is expected to have highest CAGR amongst all regions for the forecasted period of 2018-2023. APAC market is driven by growing aging population with respiratory disorders. Pollution and lifestyle changes are also driving the APAC market.

Key Companies in the global respiratory drugs and devices market include GE Healthcare, Philips Healthcare, Roche, Merck & Co., GlaxoSmithKline, Baxter International, and 97 others.

Market Segmentation

Global respiratory drugs and devices market by therapeutic devices

Global respiratory drugs and devices market by respiratory drugs

Global respiratory drugs and devices market by end users

RESEARCH METHODOLOGY

The market study of respiratory drugs and devices market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

Secondary sources include:

Financial reports of companies involved in the market

Authentic Public Databases

Whitepapers, research-papers and news blogs

Company websites and their product catalogue.

The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.

THE REPORT COVERS:

Comprehensive research methodology of Global respiratory drugs and devices Market.

This report also includes detailed and extensive market overview with Analyst insights & key market trends.

Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the Global respiratory drugs and devices Market.

Insights about market determinants which are stimulating the Global respiratory drugs and devices Market.

Detailed and extensive market segments with regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

1. REPORT SUMMARY

  • 1.1. RESEARCH METHODS AND TOOLS
  • 1.2. MARKET BREAKDOWN
    • 1.2.1. BY SEGMENTS
    • 1.2.2. BY GEOGRAPHY
    • 1.2.3. BY STAKEHOLDERS

2. MARKET OVERVIEW AND INSIGHTS

  • 2.1. DEFINITION
  • 2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
    • 2.2.1. KEY FINDINGS
    • 2.2.2. RECOMMENDATION
    • 2.2.3. CONCLUSION
  • 2.3. GAP ANALYSIS
  • 2.4. HISTORICAL ANALYSIS
  • 2.5. CURRENT MARKET TRENDS
  • 2.6. REGULATIONS
    • 2.6.1. TAX LAWS
      • 2.6.1.1. UNITED STATES
      • 2.6.1.2. EUROPEAN UNION
      • 2.6.1.3. CHINA
      • 2.6.1.4. INDIA
      • 2.6.1.5. REST OF THE WORLD
    • 2.6.2. DRUG AND DEVICE REGULATIONS
      • 2.6.2.1. UNITED STATES
      • 2.6.2.2. EUROPEAN UNION
      • 2.6.2.3. CHINA
      • 2.6.2.4. INDIA
      • 2.6.2.5. REST OF THE WORLD
  • 2.7. RESPIRATORY DISEASES
    • 2.7.1. ASTHMA
    • 2.7.2. COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)
    • 2.7.3. CYSTIC FIBROSIS
    • 2.7.4. CHRONIC BRONCHITIS
    • 2.7.5. EMPHYSEMA
    • 2.7.6. ALLERGIC RHINITIS
    • 2.7.7. OTHER

3. MARKET DETERMINANT

  • 3.1. MOTIVATORS
    • 3.1.1. PREDOMINANCE OF CHRONIC RESPIRATORY DISEASES SUCH AS ASTHMA
    • 3.1.2. OVERGROWING GERIATRIC POPULATION BASE ARE MORE PRONE TO RESPIRATORY DISEASES
    • 3.1.3. CHANGING LIFESTYLE COUPLED WITH RISE IN OBESITY
    • 3.1.4. INNOVATIONS AND DEVELOPMENT OF NEW PRODUCTS
  • 3.2. RESTRAINTS
    • 3.2.1. REIMBURSEMENTS AND STRICT GOVERNMENT REGULATIONS IN EMERGING MARKETS
    • 3.2.2. HIGH PRICE
    • 3.2.3. LIMITED AWARENESS AND AVAILABILITY IN EMERGING MARKETS
  • 3.3. OPPORTUNITIES
    • 3.3.1. GROWING DEMAND FOR REMOTE MONITORING AND HOME CARE PRODUCTS
    • 3.3.2. EMERGING MARKETS

4. MARKET SEGMENTATION

  • 4.1. RESPIRATORY DRUGS AND DEVICES BY PRODUCT
    • 4.1.1. RESPIRATORY THERAPEUTIC DEVICES
      • 4.1.1.1. RESPIRATORY POSITIVE AIRWAY PRESSURE DEVICES
        • 4.1.1.1.1. RESPIRATORY CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) DEVICES
        • 4.1.1.1.2. RESPIRATORY AUTOMATIC PAP (APAP) DEVICES
        • 4.1.1.1.3. RESPIRATORY BI-LEVEL PAP (BPAP) DEVICES
      • 4.1.1.2. RESPIRATORY MASKS
        • 4.1.1.2.1. RESPIRATORY NASAL MASKS
        • 4.1.1.2.2. RESPIRATORY FULL-FACE MASKS
        • 4.1.1.2.3. RESPIRATORY NASAL PILLOW MASKS
        • 4.1.1.2.4. RESPIRATORY ORAL MASKS
      • 4.1.1.3. RESPIRATORY VENTILATORS
        • 4.1.1.3.1. RESPIRATORY ADULT VENTILATORS
        • 4.1.1.3.2. RESPIRATORY INFANT/NEONATAL VENTILATORS
      • 4.1.1.4. RESPIRATORY NEBULIZERS
      • 4.1.1.5. RESPIRATORY HUMIDIFIERS
        • 4.1.1.5.1. RESPIRATORY HEATED HUMIDIFIERS
        • 4.1.1.5.2. RESPIRATORY PASSOVER HUMIDIFIERS
      • 4.1.1.6. RESPIRATORY OXYGEN CONCENTRATORS
        • 4.1.1.6.1. RESPIRATORY FIXED OXYGEN CONCENTRATORS
        • 4.1.1.6.2. RESPIRATORY PORTABLE OXYGEN CONCENTRATORS
      • 4.1.1.7. RESPIRATORY INHALERS
        • 4.1.1.7.1. RESPIRATORY DRY POWDER INHALERS (DPIS)
        • 4.1.1.7.2. RESPIRATORY METERED DOSE INHALERS
      • 4.1.1.8. RESPIRATORY REUSABLE RESUSCITATORS
        • 4.1.1.8.1. RESPIRATORY ADULT RESUSCITATORS
        • 4.1.1.8.2. RESPIRATORY INFANT/NEONATAL RESUSCITATORS
      • 4.1.1.9. RESPIRATORY NITRIC OXIDE DELIVERY UNITS
      • 4.1.1.10. RESPIRATORY OXYGEN HOODS
    • 4.1.2. RESPIRATORY DIAGNOSTIC AND MONITORING DEVICES
      • 4.1.2.1. RESPIRATORY PULSE OXIMETERS
        • 4.1.2.1.1. RESPIRATORY PULSE OXIMETER SENSORS
        • 4.1.2.1.2. RESPIRATORY PULSE OXIMETER EQUIPMENT
      • 4.1.2.2. RESPIRATORY CAPNOGRAPHS
      • 4.1.2.3. RESPIRATORY GAS ANALYZERS
      • 4.1.2.4. RESPIRATORY SPIROMETERS
      • 4.1.2.5. RESPIRATORY POLYSOMNOGRAPHY (PSG) DEVICES
      • 4.1.2.6. RESPIRATORY PEAK FLOW METERS
    • 4.1.3. RESPIRATORY CONSUMABLES AND ACCESSORIES METERS
      • 4.1.3.1. RESPIRATORY DISPOSABLE MASKS METERS
      • 4.1.3.2. RESPIRATORY DISPOSABLE RESUSCITATORS METERS
      • 4.1.3.3. RESPIRATORY TRACHEOSTOMY TUBES METERS
      • 4.1.3.4. RESPIRATORY NASAL CANNULAS METERS
      • 4.1.3.5. RESPIRATORY OTHER CONSUMABLES AND ACCESSORIES METERS
  • 4.2. RESPIRATORY DRUGS AND DEVICES BY RESPIRATORY DRUGS
    • 4.2.1. RESPIRATORY DRUGS BY ROUTE OF ADMINISTRATION
      • 4.2.1.1. ORAL RESPIRATORY DRUGS
      • 4.2.1.2. INJECTABLE RESPIRATORY DRUGS
      • 4.2.1.3. INHALABLE RESPIRATORY DRUGS
    • 4.2.2. RESPIRATORY DRUGS BY DRUG CLASS
      • 4.2.2.1. ANTICHOLINERGICS
      • 4.2.2.2. ANTIHISTAMINES
      • 4.2.2.3. BETA2 AGONISTS
      • 4.2.2.4. ANTIASTHMATIC COMBINATIONS
      • 4.2.2.5. CORTICOSTEROIDS
      • 4.2.2.6. LEUKOTRIENE INHIBITORS
      • 4.2.2.7. MAST CELL STABILIZERS
      • 4.2.2.8. PHOSPHODIESTERASE 4 (PDE4) INHIBITORS
      • 4.2.2.9. BRONCHODILATORS
      • 4.2.2.10. DECONGESTANTS
      • 4.2.2.11. EXPECTORANTS
      • 4.2.2.12. OTHER RESPIRATORY DRUGS
  • 4.3. RESPIRATORY DRUGS AND DEVICES BY END USERS
    • 4.3.1. HOSPITALS
    • 4.3.2. HOME CARE
    • 4.3.3. OTHER END USERS

5. COMPETITIVE LANDSCAPE

  • 5.1. KEY STRATEGY ANALYSIS
  • 5.2. KEY COMPANY ANALYSIS

6. REGIONAL ANALYSIS

  • 6.1. NORTH AMERICA
    • 6.1.1. UNITED STATES
    • 6.1.2. CANADA
    • 6.1.3. REST OF NORTH AMERICA
  • 6.2. EUROPE
    • 6.2.1. UNITED KINGDOM
    • 6.2.2. FRANCE
    • 6.2.3. GERMANY
    • 6.2.4. ITALY
    • 6.2.5. SPAIN
    • 6.2.6. REST OF EUROPE
  • 6.3. ASIA PACIFIC
    • 6.3.1. INDIA
    • 6.3.2. CHINA
    • 6.3.3. JAPAN
  • 6.4. REST OF THE WORLD

7. COMPANY PROFILES

  • 7.1. ASTRAZENECA
  • 7.2. ADAMIS (ADMP)
  • 7.3. ADS BIOTECHNOLOGY
  • 7.4. AIR LIQUIDE
  • 7.5. ALIOS BIOPHARMA INC.
  • 7.6. ALUNG TECHNOLOGIES
  • 7.7. ALVOGEN
  • 7.8. ANAXSYS
  • 7.9. APPLIED BIOCODE INC
  • 7.10. APTIMMUNE BIOLOGICS INC
  • 7.11. APTUIT
  • 7.12. ARADIGM
  • 7.13. AROS PHARMA APS
  • 7.14. ARROW THERAPEUTICS, LTD.
  • 7.15. AVITA MEDICAL
  • 7.16. BAXTER INTERNATIONAL
  • 7.17. BAYER AG
  • 7.18. BEXIMCO PHARMACEUTICALS LTD
  • 7.19. BIOMARCK PHARMACEUTICALS, LTD
  • 7.20. BIOXYDYN LIMITED
  • 7.21. BOEHRINGER INGELHEIM
  • 7.22. CAPELLON PHARMACEUTICALS, LTD.
  • 7.23. CHART INDUSTRIES
  • 7.24. CHIESI FARMACEUTICI S.P.A
  • 7.25. CIRCADIANCE
  • 7.26. CIRCASSIA.
  • 7.27. CIVITAS THERAPEUTICS, INC.
  • 7.28. COMPUMEDICS LIMITED
  • 7.29. COVIDIEN PLC
  • 7.30. DAINIPPON SUMITOMO PHARMA CO., LTD.
  • 7.31. DRAGER MEDICAL GMBH
  • 7.32. EDIMER PHARMACEUTICALS
  • 7.33. EDIXOMED LTD.
  • 7.34. ENANTA PHARMACEUTICALS
  • 7.35. FARON
  • 7.36. FISHER AND PAYKEL HEALTHCARE CORP. LTD
  • 7.37. GE HEALTHCARE LIMITED
  • 7.38. GECKO HEALTH INNOVATIONS, INC.
  • 7.39. GILBERT TECHNOLOGIES
  • 7.40. GILEAD SCIENCES, INC.
  • 7.41. GLAXOSMITHKLINE
  • 7.42. GRIFOLS
  • 7.43. H&T PRESSPART
  • 7.44. HAMILTON MEDICAL AG
  • 7.45. INVACARE CORPORATION
  • 7.46. MERCK AND CO.
  • 7.47. MERIDIAN BIOSCIENCE
  • 7.48. METHAPHARM
  • 7.49. MICROBOT MEDICAL
  • 7.50. MYLAN
  • 7.51. NABRIVA THERAPEUTICS
  • 7.52. NEPHRON PHARMACEUTICALS CORPORATION
  • 7.53. NOVABIOTICS
  • 7.54. NOVALUNG
  • 7.55. NOVARTIS AG
  • 7.56. NOX MEDICAL
  • 7.57. ONCOLYTICS BIOTECH
  • 7.58. OPKO HEALTH
  • 7.59. OREXO
  • 7.60. ORION CORPORATION
  • 7.61. OTSUKA PHARMACEUTICALS
  • 7.62. OXAGEN LIMITED
  • 7.63. OXEHEALTH
  • 7.64. PALOBIOFARMA SL
  • 7.65. PATARA PHARMA
  • 7.66. PATHWAY THERAPEUTICS LTD
  • 7.67. PEPTINNOVATE
  • 7.68. PFIZER
  • 7.69. PHARMAXIS
  • 7.70. PHARMAXIS
  • 7.71. PHILIPS HEALTHCARE
  • 7.72. PIERIS PHARMACEUTICALS
  • 7.73. PLAIR SA
  • 7.74. PMD SOLUTIONS
  • 7.75. PNEUMACARE LIMITED
  • 7.76. PROPELLER HEALTH
  • 7.77. PULMOTECT, INC.
  • 7.78. REPLICOR
  • 7.79. RESPEQ
  • 7.80. RESPICARDIA
  • 7.81. RESPIRATORY MOTION
  • 7.82. ROCHE DIAGNOSTICS
  • 7.83. SAVARA INC.
  • 7.84. SIME DIAGNOSTICS LTD
  • 7.85. SUNOVION PHARMACEUTICALS INC
  • 7.86. SYNAIRGEN
  • 7.87. SYNAPSE BIOMEDICAL
  • 7.88. TAKEDA PHARMACEUTICAL COMPANY LIMITED,
  • 7.89. TECHNO DRUGS LTD.
  • 7.90. TEICOS PHARMA OY
  • 7.91. TEIJIN PHARMA LTD.
  • 7.92. TEVA PHARMACEUTICALS
  • 7.93. TOTALCARE EHEALTH
  • 7.94. VALEANT PHARMACEUTICALS
  • 7.95. VAPOTHERM
  • 7.96. VENTIRX PHARMACEUTICALS, INC.
  • 7.97. VERONA PHARMA PLC
  • 7.98. VERTEX PHARMACEUTICALS
  • 7.99. VIDA THERAPEUTICS INC.
  • 7.100. VIRIONHEALTH LIMITED
  • 7.101. VIROBLOCK SA
  • 7.102. VIROCLINICS BIOSCIENCES B.V.
  • 7.103. WINDTREE THERAPEUTICS
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.